Cas:70362-41-3 2,3,3′,4,5′-Pentachlorobiphenyl manufacturer & supplier

We serve Chemical Name:2,3,3′,4,5′-Pentachlorobiphenyl CAS:70362-41-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2,3,3',4,5'-Pentachlorobiphenyl

Chemical Name:2,3,3′,4,5′-Pentachlorobiphenyl
CAS.NO:70362-41-3
Synonyms:1,2,3-trichloro-4-(3,5-dichlorophenyl)benzene
Molecular Formula:C12H5Cl5
Molecular Weight:326.43300
HS Code:

Physical and Chemical Properties:
Melting point:95.86°C (estimate)
Boiling point:393.3ºC at 760 mmHg
Density:1.522 g/cm3
Index of Refraction:1.619
PSA:
Exact Mass:323.88300
LogP:6.62060

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1,2,3-trichloro-4-(3,5-dichlorophenyl)benzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,2,3-trichloro-4-(3,5-dichlorophenyl)benzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,2,3-trichloro-4-(3,5-dichlorophenyl)benzene Use and application,1,2,3-trichloro-4-(3,5-dichlorophenyl)benzene technical grade,usp/ep/jp grade.


Related News: Novadiscovery (NOVA), a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, today announces the appointment of Grégoire Boutonnet as Chief Operating Officer, effective immediately. (2S,5R)-1-(L-isoleucyl)-5-ethynylpyrrolidine-2-carbonitrile manufacturers The CHMP concluded that the benefits of Zynteglo continue to outweigh its risks. As for all medicines, the EMA will monitor any new data on its safety and update advice for patients and healthcare professionals when necessary. 1-Heptyn-3-one, 6,6-diethoxy-5-hydroxy-1-(triethylsilyl)-, (5S)- suppliers Despite the $13 million first-quarter hit from the rate cut, iRhythm grew revenue year over year by 17% to $74.3 million in the quarter. iRhythm’s net losses for the quarter totaled $27.8 million, compared to a net loss of $9.1 million in the first quarter of 2020. 2α-Brom-5α,6β-dihydroxy-6α-methyl-5α-cholestanon-(3) vendor & factory.